Salmeterol is a long-acting β2-adrenergic receptor agonist that is clinically used to treat asthma and chronic obstructive pulmonary disease (COPD). Salmeterol exhibits anti-asthma, anti-fibrotic, and anti-inflammatory activities. In vitro, salmeterol decreases TGF-β-induced deposition of collagen and fibronectin.
| Cas No. | 89365-50-4 |
|---|---|
| Purity | ≥98% |
| Formula | C25H37NO4 |
| Formula Wt. | 415.57 |
| IUPAC Name | 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol |
| Solubility | Soluble in ethanol (50 mM), and DMSO (100 mM) |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Lambers C, Qi Y, Eleni P, et al. Extracellular matrix composition is modified by β2-agonists through cAMP in COPD. Biochem Pharmacol. 2014 Oct 1;91(3):400-8. PMID: 25107701.
Coleman RA. On the mechanism of the persistent action of salmeterol: what is the current position? Br J Pharmacol. 2009 Sep;158(1):180-2. PMID: 19719780.
